astria therapeutics glp-1 receptor agonist weight management diabetes treatments Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review GLP-1 Receptor Agonists and Research

10.1016/j.bbr.2012.09.021 [DOI] [PubMed] [Google Scholar] 15.Zhang L, Zhang W, Tian X (2023) The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases

Bu H, Li L, Li X, Guo J

(Meier JJ

Moreover, the SURMOUNTMMO (tirzepatide, NCT05556512) will assess the impact of the dual GLP-1/GIP RA in cardiovascular outcomes and all-cause mortality for people with obesity (without diabetes) when the REDEFINE-3 study will assess the impact of cagrisema in people with obesity (with and without T2DM) and established cardiovascular disease

DPP-4 is a serine protease that is expressed on the surface of endothelial cells, T-lymphocytes & in a circulating form

November 2023: A report filed in the Journal of the American Medical Association found a link between taking Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) and an increased risk of adverse gastrointestinal events such as gastroparesis